<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163197">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02001896</url>
  </required_header>
  <id_info>
    <org_study_id>XJTHLC001</org_study_id>
    <nct_id>NCT02001896</nct_id>
  </id_info>
  <brief_title>Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation</brief_title>
  <official_title>A Randomized, Open-label Phase III Study of First-line Treatment With Erlotinib Intercalated With Gemcitabine/ Cisplatin or Carboplatin Therapy Versus Erlotinib in Stage IIIB/IV NSCLC Patients With EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinjiang Medical University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2 arm study will compare the efficacy and safety of treatment with  erlotinib
      intercalated with platinum-based therapy or  erlotinib along, as first line treatment in
      Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor
      (EGFR) Mutation. Patients will be randomized to receive gemcitabine (1000mg/m2 iv) on days 1
      , and cisplatin (75mg/m2) or carboplatin (5xAUC)on day 1, followed by erlotinib 150mg/day
      from day 15 to day 28 of each 4 week cycle for a total of 6 cycles,then followed by
      erlotinib  monotherapy, or erlotinib 150mg/day .The anticipated time on study treatment is
      until disease progression, and the target sample size is 60 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of death from any cause,  assessed up to 24 mont</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>erlotinib combine with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: gemcitabine 1000mg/m2 iv on days 1  of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>erlotinib along</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: erlotinib [Tarceva] 150mg/day po  until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine; cisplatin or carboplatin; erlotinib</intervention_name>
    <arm_group_label>erlotinib combine with chemotherapy</arm_group_label>
    <other_name>tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <arm_group_label>erlotinib along</arm_group_label>
    <other_name>tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;=18 years of age;advanced (stage IIIB/IV)non-small cell lung
             cancer;measurable disease;ECOG Performance Status 0-2.

        Exclusion Criteria:

          -  prior exposure to agents directed at the HER axis;prior chemotherapy or systemic
             anti-tumor therapy after advanced disease;unstable systemic disease; any other
             malignancy within last 5 years, except cured basal cell cancer of skin or cured
             cancer in situ of cervix.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Shan, Master</last_name>
    <phone>13609989394</phone>
    <email>shanlinew319@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiang Wang, Master</last_name>
    <phone>13579960434</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xinjiang medical university</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>XJTHLC001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Shan, Master</last_name>
      <phone>13609989394</phone>
      <email>shanlinew319@163.com</email>
    </contact>
    <investigator>
      <last_name>Qiang Wang, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 28, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinjiang Medical University</investigator_affiliation>
    <investigator_full_name>li shan</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>EGFR-TKI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
